Neoadjuvant relatlimab and nivolumab in resectable melanoma (vol 611, pg 155, 2022)

被引：1
|
作者：
Amaria, Rodabe N.
Postow, Michael
Burton, Elizabeth M.
Tetzlaff, Michael T.
Ross, Merrick I.
Torres-Cabala, Carlos
Glitza, Isabella C.
Duan, Fei
Milton, Denai R.
Busam, Klaus
Simpson, Lauren
McQuade, Jennifer L.
Wong, Michael K.
Gershenwald, Jeffrey E.
Lee, Jeffrey E.
Goepfert, Ryan P.
Keung, Emily Z.
Fisher, Sarah B.
Betof-Warner, Allison
Shoushtari, Alexander N.
Callahan, Margaret
Coit, Daniel
Bartlett, Edmund K.
Bello, Danielle
Momtaz, Parisa
Nicholas, Courtney
Gu, Aidi
Zhang, Xuejun
Korivi, Brinda Rao
Patnana, Madhavi
Patel, Sapna P.
Diab, Adi
Lucci, Anthony
Prieto, Victor G.
Davies, Michael A.
Allison, James P.
Sharma, Padmanee
Wargo, Jennifer A.
Ariyan, Charlotte
Tawbi, Hussein A.
机构：
来源：
NATURE | 2023年 / 615卷 / 7953期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1038/s41586-023-05892-1
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：E23 / E23
页数：1
相关论文
共 50 条
  • [41] A Case of Vanishing Brain Metastasis in a Melanoma Patient on Nivolumab (vol 36, pg 4795, 2016)
    Basnet, A.
    ANTICANCER RESEARCH, 2016, 36 (11) : 6205 - 6205
  • [42] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (vol 377, pg 1345, 2017)
    Larkin, J.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J. J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Dummer, R.
    Smylie, M.
    Rutkowski, P.
    Ferrucci, P. F.
    Hill, A.
    Wagstaff, J.
    Carlino, M. S.
    Haanen, J. B.
    Maio, M.
    Marquez-Rodas, I.
    McArthur, G. A.
    Ascierto, P. A.
    Long, G. V.
    Callahan, M. K.
    Postow, M. A.
    Grossmann, K.
    Sznol, M.
    Dreno, B.
    Bastholt, L.
    Yang, A.
    Rollin, L. M.
    Horak, C.
    Hodi, F. S.
    Wolchok, J. D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (22): : 2185 - 2185
  • [43] A Case of Vanishing Brain Metastasis in a Melanoma Patient on Nivolumab (vol 36, pg 4795, 2016)
    Basnet, A.
    ANTICANCER RESEARCH, 2016, 36 (12) : 6918 - 6918
  • [44] Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma (vol 34, pg 806, 2023)
    Sharon, C. E.
    Tortorello, G. N.
    Ma, K. L.
    Huang, A. C.
    Xu, X.
    Giles, L. R.
    Mcgettigan, S.
    Kreider, K.
    Schuchter, L. M.
    Mathew, A. J.
    Amaravadi, R. K.
    Gimotty, P. A.
    Miura, J. T.
    Karakousis, G. C.
    Mitchell, T. C.
    ANNALS OF ONCOLOGY, 2024, 35 (08) : 756 - 756
  • [45] Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.
    Lucas, Minke W.
    Arokoski, Reetta
    Menzies, Alexander M.
    Pulleman, Saskia
    Saw, Robyn P. M.
    van Houdt, Winan J.
    Faries, Mark B.
    Robert, Caroline
    Ascierto, Paolo Antonio
    Lebbe, Celeste
    Carlino, Matteo S.
    Kapiteijn, Ellen
    Suijkerbuijk, Karijn
    Rutkowski, Piotr
    Sandhu, Shahneen
    Van Der Veldt, Astrid Aplonia Maria
    Long, Georgina V.
    Blank, Christian U.
    van de Poll-franse, Lonneke
    Lijnsvelt, Judith
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA9584 - LBA9584
  • [46] Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high risk resectable melanoma (MEL): Preliminary results
    Davar, Diwakar
    Karunamurthy, Arivarasan
    Hartman, Douglas
    Ka, Mignane
    Menna, Carmine
    Burkette, Julie
    Chauvin, Joe-Marc
    Rubuffet, Lucas
    Zhang, Shuowen
    Ding, Quanquan
    Rose, Amy
    Sellitto, Kellie
    Najjar, Yana
    Holtzman, Matthew
    Pingpank, James
    Sridharan, Shaum
    Duvvuri, Umamaheshwar
    Youssoufian, Hagop
    Labinger, Barry
    Krieg, Arthur
    Kirkwood, John
    Zarour, Hassane
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [47] Epidemiological Study Regarding the Incidence of Venous Thromboembolism in Patients After Cancer Remission (vol 11, pg 611, 2022)
    Imura, Miki
    Katada, Jun
    Shiga, Taro
    CARDIOLOGY AND THERAPY, 2023, 12 (04) : 749 - 749
  • [48] Nivolumab induces long-term remission in a patient with fusariosis (vol 173, pg 91, 2022)
    Khatamzas, Elham
    Mellinghoff, Sibylle C.
    Thelen, Martin
    Schloesser, Hans A.
    Kunz, Wolfgang G.
    Buerkle, Carolin
    Dichtl, Karl
    Guenther, Michael
    Ormanns, Steffen
    von Bergwelt-Baildon, Michael
    EUROPEAN JOURNAL OF CANCER, 2023, 181 : 208 - 209
  • [49] Addressing historical trauma and healing in Indigenous language cultivation and revitalization (vol 42, pg 155, 2022)
    McKenzie, James
    ANNUAL REVIEW OF APPLIED LINGUISTICS, 2022, 42 : 155 - 155
  • [50] First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data (vol 42, 33, 2024)
    Long, Georgina V.
    Lipson, Evan J.
    Hodi, F. Stephen
    Ascierto, Paolo A.
    Larkin, James
    Lao, Christopher
    Grob, Jean-Jacques
    Ejzykowicz, Flavia
    Moshyk, Andriy
    Garcia-Horton, Viviana
    Zhou, Zheng-Yi
    Xin, Yiqiao
    Palaia, Jennell
    McDonald, Laura
    Keidel, Sarah
    Salvatore, Anthony
    Patel, Divya
    Sakkal, Leon A.
    Tawbi, Hussein
    Schadendorf, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (11) : 1398 - 1398
12345